Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: A retrospective study on the risk factors and the efficacy of treatment

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 8, 2005, Pages 411-415

  Patel, Soonie R ^a   Ridwan, Rudy U ^a   Ortín, Miguel ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Allogeneic hemopoietic progenitors transplant; Children; Cytomegalovirus reactivation

Indexed keywords

ACICLOVIR; GANCICLOVIR; PHOSPHOPROTEIN; SYNAPTOTAGMIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ANTIGEN DETECTION; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; VIRUS REACTIVATION;

ADOLESCENT; CHILD; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 24144431577     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000174242.80167.9d     Document Type: Article

References (24)

1. Paulin T, Ringdén O, Lönnqvist B, et al. The importance of pre-bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors. Scand J Infect Dis. 1986;18:199-209.
2. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478-488.
3. Goodrich JM, Mori M, Gleaves CA, et al. Early management with ganciclovir to prevent CMV disease after allogeneic bone marrow transplant. N Engl J Med. 1991;325:1601-1607.
4. Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in paediatric transplant recipients. Paediatr Drugs. 2002;4:279-290.
5. Hazar V, Kansoy S, Kupesiz A, et al. High-dose acyclovir and pre-emptive ganciclovir in the prevention of CMV disease in paediatric patients following peripheral blood SCT. Bone Marrow Transplant. 2004;33:931-935.
6. Yanada M, Yamamoto K, Emi N, et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing HSCT. Bone Marrow Transplant. 2003;32:801-807.
7. Dumont-Girard F, Roux E, Van Lier RA. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood. 1998;92:4464-4471.
8. de Vries E, van Tol MJD, Langlois van den Bergh R, et al. Reconstitution of lymphocyte subpopulations after paediatric marrow transplantation. Bone Marrow Transplant. 2000;25:267-275.
9. Kano Y, Shiohara T. Current understanding of cytomegalovirus infection in immunocompetent individuals. J Dermatol Sci. 2000;22:196-204,
10. Hakim FT, Gress RE. Reconstitution of thymic function after stem cell transplantation in humans. Curr Opin Haematol. 2002;9:490-496.
11. Lewin SR, Heller G, Zhang L, et al. Direct evidence for new T-cell generation by patients of either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplants. Blood. 2002;100:2235-2242.
12. Reusser P, Riddell SR, Meyers JD. Cytotoxic T-lymphocyte response to CMV after human allogeneic bone marrow transplant: pattern of recovery and correlation with CMV infection and disease. Blood. 1991;78:1373-1380.
13. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualisation of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97:1232-1240.
14. Aubert G, Hassan-Walker AF, Madrigal JA, et al. Cytomegalovirus-specific cellular immune response and viremia in recipients of allogeneic stem cell transplants. J Infect Dis. 2001;184:955-963.
15. Meyers JD, Flournoy N, Thomas ED. Cytomegalovirus infection and specific cell-mediated immunity after transplant. J Infect Dis. 1980;142:816-824.
16. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97:1458-1466.
17. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV seropositive recipients after unrelated donor stem cell transplant; an EBMT megafile analysis. Blood. 2003;102:4255-4260.
18. Boeckh M, Huang M, Ferrenberg J, et al. Optimisation of quantitative detection of CMV DNA in plasma by RT-PCR. J Clin Microbiol. 2004;42:1142-1148.
19. Lerhez-Ville M, Onachee M, Delarue R, et al. Monitoring CMV infection in adult and paediatric BMT recipients by a real time-PCR assay performed by blood plasma. J Clin Microbiol. 2003;41:2040-2046.
20. Meijer E, Boland GJ, Verdnck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev. 2003;16:647-657.
21. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for the prevention of CMV infection and disease after allogeneic BMT. N Engl J Med. 1988;318:70-75.
22. Prentice HG, Gluckman E, Powles RL, et al. Long-term survival in allogeneic BMT recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant. 1997;19:129-133.
23. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenaemia-guided early treatment with ganciclovir at engraftment after allogeneic marrow transplantation: a randomised double blind study. Blood. 1996;88:4063-4071.
24. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted CMV specific T-cell responses after allogeneic BMT: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971-1979.